MILWAUKEE--(BUSINESS WIRE)-- The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, 2seventy bio shareolders will receive only $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. 2seventy bio insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for 2seventy bio by imposing a significant penalty if 2seventy bio accepts a competing bid. We are investigating the conduct of the 2seventy bio board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250311485895/en/